Bal Pharma Ltd

Bal Pharma Ltd

Bal Pharma Ltd has fixed September 17, 2026, as the record date for payment of a final dividend of Rs. 1.20 per share. The dividend will be paid on or after September 24, 2026, to members holding equity shares as on the record date. The company will deduct tax at source (TDS) from the dividend payment, and shareholders are required to submit forms and declarations to avail of Nil or lower rate of tax deduction.

Bal Pharma Ltd

Bal Pharma Ltd has released its Annual Report 2025-26, as per SEBI Listing Regulations, along with the Notice of the 39th AGM. The report is available on the company's website.

Bal Pharma Ltd

Bal Pharma Ltd has scheduled its 39th Annual General Meeting (AGM) on September 24, 2026, to consider various resolutions, including the re-appointment of a director and the ratification of the remuneration payable to cost auditors.

Bal Pharma Ltd

Bal Pharma Ltd has scheduled its 39th Annual General Meeting (AGM) to be held on September 24, 2026, through video conferencing. The record date for determining the eligibility of members entitled to receive the final dividend for the financial year 2025-26 is September 17, 2026. The book closure period is from September 18 to September 24, 2026.

Bal Pharma Ltd

Bal Pharma Ltd clarifies the timeline for utilization of net proceeds of preferential issue, stating it is 18 months from allotment date, in accordance with SEBI regulations.

Bal Pharma Ltd

Bal Pharma Ltd has published unaudited financial results for the quarter ended June 30, 2026, and an IEPF notice regarding unclaimed dividends for FY 2018-19 and onwards.

Bal Pharma Ltd

Bal Pharma Ltd has announced its unaudited standalone and consolidated financial results for the first quarter ended June 30, 2026, with a limited review report from the statutory auditors, M/s. SSJNB & Co, with an unmodified opinion.

Bal Pharma Ltd

Bal Pharma Ltd's board of directors met on August 12, 2026, and approved unaudited financial results for the quarter ended June 30, 2026. The board also approved changes in designations of two directors, a joint venture proposal, and the allotment of warrants to a promoter.

Bal Pharma Ltd

Bal Pharma Ltd's scrutinizer's report on postal ballot voting has been submitted, with no rejections or modifications received from shareholders after the issuance of a corrigendum. The voting process was conducted electronically, and the results will be considered as the final voting.

Bal Pharma Ltd

Bal Pharma Ltd has announced the outcome of its postal ballot, where the shareholders approved the issue of 10,00,000 Warrants to the Promoter on a preferential basis. The voting results showed 99.96% of the total votes received in favor of the resolution, with only 0.04% against it.

Bal Pharma Ltd

Bal Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 12/08/2026 to consider and approve the Unaudited (Standalone and Consolidated) Financial Statements for the first quarter ended 30th June 2026 and other general business matters.

Bal Pharma Ltd

Bal Pharma Ltd provides an opportunity to shareholders to submit comments on the corrigendum to the postal ballot notice within 48 hours.

Bal Pharma Ltd

Bal Pharma Ltd has issued a corrigendum to its postal ballot notice dated 09th July 2026, revising the issue price of warrants from ₹81/- to ₹84/- per warrant, including a premium of ₹74/- per warrant. The aggregate consideration for the proposed issue of 10,00,000 (Ten Lakh) warrants shall stand revised from ₹8,10,00,000/- to ₹8,40,00,000/-.